Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis

• Published in: Proceedings of the National Academy of Sciences - PNAS Vol. 95; no. 20; p. 11891
• Main Authors: Belinsky, S A, Nikula, K J, Palmisano, W A, Michels, R, Saccomanno, G, Gabrielson, E, Baylin, S B, Herman, J G
• Format: Journal Article
• Language: English
• Published: United States 29.09.1998
• Subjects: Adenoma - genetics; Adenoma - metabolism; Animals; Biomarkers, Tumor; Carcinogens - toxicity; Carcinoma in Situ - genetics; Carcinoma in Situ - metabolism; Carcinoma, Squamous Cell - diagnosis; Carcinoma, Squamous Cell - genetics; Carcinoma, Squamous Cell - metabolism; DNA Methylation; DNA, Neoplasm - genetics; DNA, Neoplasm - metabolism; Genes, p16; Humans; Hyperplasia; Lung Neoplasms - diagnosis; Lung Neoplasms - genetics; Lung Neoplasms - metabolism; Metaplasia; Nitrosamines - toxicity; Precancerous Conditions - genetics; Precancerous Conditions - metabolism; Rats; Rats, Inbred F344; Sputum - cytology; Sputum - metabolism
• ISSN: 0027-8424
• DOI: 10.1073/pnas.95.20.11891

The p16(INK4a) (p16) tumor suppressor gene can be inactivated by promoter region hypermethylation in many tumor types including lung cancer, the leading cause of cancer-related deaths in the U.S. We have determined the timing of this event in an animal model of lung carcinogenesis and in human squamous cell carcinomas (SCCs). In the rat, 94% of adenocarcinomas induced by the tobacco specific carcinogen 4-methylnitrosamino-1-(3-pyridyl)-1-butanone were hypermethylated at the p16 gene promoter; most important, this methylation change was frequently detected in precursor lesions to the tumors: adenomas, and hyperplastic lesions. The timing for p16 methylation was recapitulated in human SCCs where the p16 gene was coordinately methylated in 75% of carcinoma in situ lesions adjacent to SCCs harboring this change. Moreover, the frequency of this event increased during disease progression from basal cell hyperplasia (17%) to squamous metaplasia (24%) to carcinoma in situ (50%) lesions. Methylation of p16 was associated with loss of expression in both tumors and precursor lesions indicating that both alleles were functionally inactivated. The potential of using assays for aberrant p16 methylation to identify disease and/or risk was validated by detection of this change in sputum from three of seven patients with cancer and 5 of 26 cancer-free individuals at high risk. These studies show for the first time that an epigenetic alteration, aberrant methylation of the p16 gene, can be an early event in lung cancer and may constitute a new biomarker for early detection and monitoring of prevention trials.